Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Short term Debt: 2022-2023

  • bioAffinity Technologies' Short term Debt was N/A to $42,334 in Q2 2023 from the same period last year, while for Jun 2023 it was $42,334, marking a year-over-year change of. This contributed to the annual value of $251,746 for FY2022, which is N/A change from last year.
  • According to the latest figures from Q2 2023, bioAffinity Technologies' Short term Debt is $42,334, which was down 74.87% from $168,430 recorded in Q1 2023.
  • bioAffinity Technologies' 5-year Short term Debt high stood at $500,000 for Q3 2022, and its period low was $42,334 during Q2 2023.
  • Over the past 2 years, bioAffinity Technologies' median Short term Debt value was $210,088 (recorded in 2022), while the average stood at $240,628.